COA ↓

Product

COA Doc

SYN-2621

99.0% Purity SYN-2621 Research Grade HPLC Verified

Semaglutide

GLP-1 Receptor Agonist · Research Grade

Select Strength — 5mg

$65.00

C₁₈₇H₂₉₁N₄₅O₅₉ MW: 4113.58 g/mol CAS: 910463-68-2

Out of Stock

Notify me when back in stock

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

99.0%

HPLC Purity

Lot Number SYN-2621-SEMA

Test Date March 2026

Labeled 10 mg

Actual 10.00 mg

99.1%

HPLC Purity

Lot Number SYN-2520-SEMA

Test Date August 2026

Labeled 10 mg

Actual 10.01 mg

Research Data

KEY FINDINGS

🧬

14.9%

Body Weight Reduction (STEP-1)

Phase III STEP-1 trial at 68 weeks — Wilding JPH et al., NEJM 2021

🔬

20%

CV Event Reduction (SELECT)

20% major adverse cardiovascular event reduction — SELECT trial, 2023

✅

98.1%

HPLC-Verified Purity

Current batch SYN-2621, third-party accredited lab

❄️

24mo

Lyophilised Shelf Life

At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

📉 Phase III STEP-1 Trial

14.9% Weight Loss — The Pivotal Obesity Trial

Wilding et al. published the STEP-1 Phase III trial (N=1,961) in NEJM 2021, demonstrating 14.9% mean body weight reduction at 68 weeks with semaglutide 2.4mg — at the time the largest RCT weight loss result ever published. FDA approved Wegovy based on this data.

🔬 −14.9% mean weight loss at 68 weeks — the Phase III result that redefined the standard of care for obesity pharmacotherapy.

PMID 33567185 — NEJM

🫀 Cardiovascular Outcomes

SELECT Trial — 20% MACE Reduction

The SELECT trial (2023, N=17,604) demonstrated semaglutide 2.4mg reduced major adverse cardiovascular events by 20% in overweight/obese adults without diabetes at 33 months — expanding the indication beyond weight management into cardiovascular risk reduction.

🔬 20% MACE reduction in SELECT trial — first weight-loss drug to demonstrate cardiovascular mortality benefit in non-diabetic obesity.

PMID 37952131 — NEJM (SELECT)

14.9 %

Phase III STEP-1 — 14.9% Weight Reduction at 68 Weeks

Semaglutide is the GLP-1 receptor agonist active in Ozempic and Wegovy. The STEP-1 Phase III trial demonstrated 14.9% mean body weight reduction at 68 weeks — the largest randomised controlled trial weight loss outcome in history at the time of publication.

STEP-1 Trial Weight Loss — Semaglutide 2.4mg vs. Placebo

Semaglutide 2.4mg −14.9%

Placebo −2.4%

Source: Wilding JPH et al., NEJM, 2021

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2621-SEMA

Specification	Value
CAS Number	910463-68-2
Molecular Formula	C₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight	4113.58 g/mol
Purity (HPLC)	99.0%
Appearance	White lyophilised powder
Solubility	Soluble in water (1 mg/mL)
Storage	−20°C long-term / 2–8°C short-term
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

14.9 %

Mean Body Weight Reduction at 68 Weeks vs. 2.4% Placebo

Semaglutide 2.4mg −14.9%

Placebo −2.4%

Comparative Activity Profile

Semaglutide Tirzepatide

Observed Adverse Indicators

Cardiovascular adverse events

None

Hepatotoxicity

None

Nausea (GLP-1 class effect)

Minimal

Injection site reactions

Minimal

⚠️ Theoretical Concern

GLP-1 Class GI Effects — Dose-Dependent Nausea

Nausea and GI discomfort are the primary adverse events associated with semaglutide, consistent across all GLP-1 receptor agonists. These effects are dose-dependent, typically transient during dose escalation, and do not represent hepatic or cardiovascular risk.

FDA-approved with extensive Phase III safety data from STEP-1, STEP-2, STEP-3, STEP-4, and SELECT trials
SELECT trial (N=17,604): 20% MACE reduction — positive cardiovascular safety profile confirmed
GI adverse events are class-specific and transient — no serious organ toxicity identified in Phase III database

Semaglutide

BATCH VERIFICATION

KEY FINDINGS

IN VITRO RESEARCH OVERVIEW

14.9% Weight Loss — The Pivotal Obesity Trial

SELECT Trial — 20% MACE Reduction

PURITY VERIFICATION

TRIAL RESULTS

SAFETY PROFILE

GLP-1 Class GI Effects — Dose-Dependent Nausea

FREQUENTLY ASKED QUESTIONS

RESEARCH CITATIONS